 There is an urgent need to find safe, effective means of preventing mother-to-child-transmission MTCT of HIV that can be used in developing countries. One of the greatest obstacles to prevention in these areas remains HIV transmission through breast milk. The primary purpose of this trial is to determine if nevirapine NVP plus immunoprophylaxis by intravenous HIV immune globulin HIVIGLOB or extended NVP dosing of the neonate during the perinatal period can safely and effectively reduce the risk of peripartum or early breastfeeding-related HIV MTCT. 